The low levels of plasma ceruloplasmin (Table S2) observed in the WD patient containing these mutations could be explained by this cellular phenotype, however direct measurements of copper-transport activities of heterodimer (using tyrosinase assay or copper retention) will be necessary to fully understand consequences of compound heterozygosity on ATP7B properties. The gene discussed is TYR; the disease is Wilson disease.